Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAEF-AVF study of fasudil hydrochloride during arteriovenous fistula creation
jRCTs031220704Active, not recruiting
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of fasudil in end-stage kidney disease (ESKD). Primary endpoint: Incidence of hypotension and bleeding complications. Started May 2023; status: active, not recruiting.
02
Drugs
fasudil
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on jRCTs031220704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220704.